Key result
Intravenous pentoxifylline 300 mg had no significant effect on regional cerebral blood flow compared to placebo in healthy subjects.
Why the study?
Does intravenous pentoxifylline 300 mg increase regional cerebral blood flow and dilate large arteries in healthy subjects?
Population
10 healthy subjects
Comparison
Pentoxifylline 300 mg intravenously vs Placebo intravenously on separate days
Design
RCT, double-blind
Authors
Loading...
No acute cerebral vasodilatory effect in healthy subjects; challenges vascular mechanism assumptions for stroke and redirects research to non-vascular pathways.
RCT (n=10)
Double-blind
Does intravenous pentoxifylline 300 mg increase regional cerebral blood flow and dilate large arteries in healthy subjects?
Intravenous pentoxifylline does not significantly increase regional cerebral blood flow or dilate large arteries in healthy subjects, suggesting its potential benefits in stroke are mediated by non-vascular mechanisms.
Kruuse et al. (2000) conducted an RCT in Healthy (n=10). Pentoxifylline vs. Placebo was evaluated on regional cerebral blood flow (rCBF). Intravenous pentoxifylline 300 mg had no significant effect on regional cerebral blood flow compared to placebo in healthy subjects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: